Now showing items 2-4 of 4

    • Genome scan of human systemic lupus erythematosus: Evidence for linkage on chromosome 1q in African-American pedigrees 

      Moser, Kathy L.; Neas, Barbara R.; Salmon, Jane E.; Yu, Hua; Gray-McGuire, Courtney; Asundi, Neeraj; Bruner, Gail R.; Fox, Jerome; Kelly, Jennifer; Henshall, Stephanie; Bacino, Debra; Dietz, Myron; Hogue, Robert; Koelsch, Gerald; Nightingale, Lydia; Shaver, Tim; Abdou, Nabih I.; Albert, Daniel A.; Carson, Craig; Petri, Michelle; Treadwell, Edward L.; James, Judith A.; Harley, John B. (East Carolina University, 1998-12)
      Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by production of autoantibodies against intracellular antigens including DNA, ribosomal P, Ro (SS-A), La (SS-B), and the spliceosome. Etiology is ...
    • Thoracolumbar compression fractures presenting with an acute ileus. 

      Treadwell, Edward L.; Cunningham, Paul R. G.; Kowalski, Henry M.; Weaver, Michael D. (East Carolina University, 1990-09)
      Corticosteroids are commonly used in the treatment of connective tissue diseases such as systemic lupus erythematosus. Although they are usually efficacious, osteoporosis leading to spine compression fractures is not ...
    • Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy 

      Baraf, Herbert S. B.; Becker, Michael A.; Gutierrez-Urena, Sergio R; Treadwell, Edward L; Vazquez-Mellado, Janitzia; Rehrig, Claudia D; Ottery, Faith D; Sundy, John S; Yood, Robert A (2013)
      INTRODUCTION: Two replicate randomized, placebo-controlled six-month trials (RCTs) and an open-label treatment extension (OLE) comprised the pegloticase development program in patients with gout refractory to conventional ...